Darling Ingredients health brand Rousselot is introducing its gelatin prototype lineup to CompaMed attendees this week during one of the world’s largest medical trade fairs in Düsseldorf, Germany.

Visitors to the company’s booth (AK14, Hall 8) during the four-day show (Nov. 17-20) will discover gelatin’s advantages as a high-performance medtech biomaterial. Rousselot is giving attendees the chance to explore application-driven prototypes including hemostats, dermal fillers, and microneedles, all of which are designed to accelerate medical device development and reduce time to market.

Among the highlights on display are:

• Gelatin-based films and foams used for hemostatic sponges or anti-adhesion films, which offer targeted performance and excellent handling properties for device development
• Flowable hemostats with customizable viscosity, bio resorption, and hemostatic efficiency for meeting product requirements 
• Dermal fillers, where gelatin enables customized rheology, injectability, and biocompatibility
• Microneedle prototypes that show gelatin’s ability to help optimize mechanical strength, dissolution rates, and active ingredient delivery

Gelatin is valued by developers of advanced medical technologies for its physicochemical properties and biocompatibility. Rousselot’s modified and non-modified gelatin portfolio is highly regarded for its high purity, consistent quality, and comprehensive regulatory documentation, according to the company. These attributes, executives claim, help medical device manufacturers reduce variability in preclinical and clinical development, supporting fast track to market.

Rousselot is a global developer of gelatin- and collagen-based solutions for the food, health/nutrition, biomedical, and pharmaceutical industries. Working with its customers, the company uses its technical expertise, sustained scientific research, and state-of-the-art operations to deliver advanced ingredient solutions that enable innovation and contribute to public health.